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a  b  s  t  r  a  c  t
Cells  with  DNA  repair  defects  have  increased  genomic  instability  and  are  more  likely  to  acquire  secondary
mutations  that  bring  about  cellular  transformation.  We  describe  the  frequency  and  spectrum  of  somatic
mutations  involving  several  tumor  suppressor  genes  in the  rectal  carcinoma  of  a 13-year-old  girl  har-
boring  biallelic,  germline  mutations  in the  DNA  mismatch  repair  gene  PMS2.  Apart  from  microsatellite
instability,  the  tumor  DNA  contained  a number  of  C:G  →  T:A  or G:C  →  A:T  transitions  in  CpG  dinucleotides,
which  often  result  through  spontaneous  deamination  of  cytosine  or 5-methylcytosine.  Four  DNA  glyco-
sylases, UNG2,  SMUG1,  MBD4  and  TDG,  are  involved  in  the repair  of  these  deamination  events.  Weolorectal cancer
MMR-D syndrome
MR  repair
upermutator
identiﬁed  a  heterozygous  missense  mutation  in  TDG,  which  was  associated  with  TDG  protein  loss  in  the
tumor.  The  CpGs  mutated  in  this  patient’s  tumor  are  generally  methylated  in  normal  colonic  mucosa.
Thus,  it  is highly  likely  that  loss  of  TDG  contributed  to  the  supermutator  phenotype  and  that  most  of  the
point  mutations  were  caused  by deamination  of  5-methylcytosine  to thymine,  which  remained  uncor-
rected  owing  to the  TDG  deﬁciency.  This  case  provides  the  ﬁrst in vivo  evidence  of  the  key  role  of  TDG  in
protecting  the  human  genome  against  the  deleterious  effects  of  5-methylcytosine  deamination.
 . Introduction
Genomic DNA is constantly exposed to endogenous and exoge-
ous damaging agents. As failure to repair this damage leads to
utations, rearrangements and other deleterious events that can
ause cellular malfunction, all living organisms have evolved efﬁ-
ient DNA repair pathways that safeguard their genomes. Two
ey guardians of genomic integrity are mismatch repair (MMR)
nd base excision repair (BER). MMR  addresses mismatches and
mall insertion/deletion loops that arise during replication and that
ould give rise to point- and frameshift mutations if left unre-
aired. BER removes predominantly aberrant DNA bases arising
hrough hydrolysis and oxidation in non-replicating DNA.
Malfunction of both MMR  and BER are associated with can-
er. Heterozygous (monoallelic) germline mutations in the MMR
enes MSH2,  MSH6, MLH1,  and PMS2 are linked to the autosomal-
ominant Lynch syndrome [1],  which predisposes primarily to
∗ Corresponding author. Tel.: +420 224 433 521; fax: +420 224 433 520.
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colorectal and endometrial cancers [2].  Lynch syndrome tumors
lose the wild type MMR allele through somatic mutations or
LOH. However, there are also rare cases of individuals with bial-
lelic germline mutations in one of the MMR  genes. These are
referred to as constitutional MMR-deﬁciency (CMMR-D) patients,
who  develop mainly childhood hematological malignancies and/or
brain tumors, as well as very early onset colorectal cancers. Most
CMMR-D patients display also signs reminiscent of neuroﬁbro-
matosis type 1, such as café au lait spots [3].
The hallmark of MMR-deﬁcient colorectal cancers is microsatel-
lite instability (MSI), which is manifested as an accumulation of
somatic frameshift mutations in runs of mono- or dinucleotides
known as microsatellites. In these tumors, frameshift mutations
are frequently found in the coding sequences of genes involved in
the control of growth regulation (TGFßRII, IGF2R,  BAX) or DNA repair
(MSH3, MSH6),  the dysregulation of which promotes tumorigenesis.
Frameshift mutations were described also in APC [4], a key tumor
suppressor gene in the Wnt  signaling pathway, the malfunction of
Open access under CC BY-NC-ND license.which has been linked to the initiation of colorectal tumorigenesis
[5].
The link between BER deﬁciency and cancer is currently limited
to the autosomal-recessive MUTYH-associated polyposis syndrome
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MAP) [6,7]. In resting DNA, 8-oxoguanines (Go) are removed by
GG1, but failure to remove this aberrant base prior to replication
ives rise to Go/A mispairs. MUTYH glycosylase removes the mis-
aired adenine and the repair polymerases insert a C opposite the
o, which provides OGG1 with a second chance at repair. Germline
utations in MUTYH result in G → T transversion mutations, which
re a hallmark of MAP.
To date, no cancer-associated mutations have been identiﬁed in
ther BER genes. This might seem unexpected, given that spon-
aneous deamination of cytosine to uracil represents a frequent
ccurrence. However, the removal of uracil from DNA can be
ccomplished by at least four glycosylases: UNG2, SMUG1, MBD4
r TDG [8].  With this degree of redundancy, inactivation of a single
ene would not be expected to have phenotypic consequences. In
ontrast, deamination of 5-methylcytosine gives rise to T/G mis-
airs, which have been shown to be repaired by BER to C/G with
he help of MBD4 or TDG. We  have been unable to detect MBD4
ctivity in extracts of human 293T cells depleted of TDG [9] and it
hus appears likely that the latter enzyme is principally responsible
or the repair of 5-methylcytosine deamination.
In this report, we describe a patient with biallelic germline PMS2
utations who developed a very early onset rectal cancer with
 particular supermutator phenotype. Intriguingly, although the
nalysis of the tumor DNA revealed MSI  at noncoding and intronic
epeats, frameshift mutations were not detected in several ana-
yzed tumor suppressor genes. In contrast, an exceedingly high
umber of somatic C:G → T:A or G:C → A:T transitions were iden-
iﬁed in these genes, many in CpG dinucleotides.
. Material and methods
.1. Microsatellite instability (MSI) analysis
Five quasi-monomorphic mononucleotide repeat markers, i.e.
AT-26, BAT-25, NR-21, NR-24, and MONO-27 were investigated
o assess MSI  employing a ﬂuorescence-based pentaplex-PCR assay
Ingenetix, Vienna, Austria) according to the manufacturer’s recom-
endations.
.2. Immunohistochemical analysis of mismatch repair proteins
nd of the base excision repair protein TDG
Sections of formalin-ﬁxed, parafﬁn-embedded tumors were
mmunostained with primary monoclonal antibodies against the
MR  proteins MSH2 (Ab NA27, Calbiochem), MSH6 (Ab 610919,
D), MLH1 (Ab 551091, BD), and PMS2 (Ab 556415, BD), as
escribed previously [10]. An afﬁnity-puriﬁed rabbit anti human
DG antibody was kindly provided by Dr. P. Schär (University
f Basel, Switzerland) and tissue immunostaining was performed
sing the protocol described in [10]. This latter antibody was
iluted 1:1500, and incubated with tissue sections overnight at
◦C.
.3. Mutation analysis in tumor tissue
DNA was extracted from fresh frozen (−70 ◦C) colorectal tissues
sing Genomic DNA Puriﬁcation Kit (Gentra Systems, Minneapolis,
I,  USA) according to manufacturer’s recommendations. Somatic
utation analysis of the APC, KRAS, TP53, BRAF, CTNNB1, MUTYH
enes, as well as examination of MSI  and MLH1 promoter hyper-
ethylation were performed as described previously [11]. The
LH1 and MSH2 genes were pre-screened for mutations by dena-uring gradient gel electrophoresis (DGGE) as described in [12]
nd PCR fragments showing an aberrant DGGE proﬁle were sub-
equently sequenced to determine the underlying mutation. The
SH6 and NF1 genes were analyzed by direct sequencing of allir 11 (2012) 616– 623 617
exons ampliﬁed directly from tumor DNA using published primers
[13,14]. Equally, the BER genes, UNG2,  SMUG1, MBD4 and TDG, were
sequenced directly from tumor DNA (primers for ampliﬁcation of
BER genes are listed in Supplementary Table 1). All mutations found
in tumor DNA were analyzed also in DNA from the corresponding
normal mucosa to exclude their presence in the germline.
Mutant allele-speciﬁc PCR ampliﬁcation [15] was used to assess
whether two somatic stop mutations identiﬁed in APC exon 6 were
located in trans or in cis.  A forward primer (5′ GTTTCTTGTTT-
TATTTTAGT 3′) with the terminal 3′ nucleotide speciﬁc for the
ﬁrst mutation (c.646C>T, p.R216*), and a reverse primer (5′ CTAC-
CTATTTTTATACCCAC 3′) positioned downstream of the second
mutation (c.694C>T, p.R232*), were used for PCR and subsequent
sequencing of the generated PCR product.
DNA from three additional CMMR-D patients (see Section 3) was
isolated from parafﬁn-embedded tumor tissue using Puregene Tis-
sue Kit (Gentra Systems, Minneapolis, MI,  USA) according to the
manufacturer’s recommendations. For somatic mutation analysis
in these tumors, APC (speciﬁed in Table 2) was ampliﬁed using
primers published in [16], and CTNNB1 exon 3 was  ampliﬁed with
the following primers: forward, 5′ CAATCTACTAATGCTAATACT-
GTTTCG 3′; reverse, 5′ GTTCTCAAAACTGCATTCTGACTTTC 3′. The
resulting PCR products were sequenced in both directions.
All cycle sequencing reactions were performed using the BigDye
Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Fos-
ter City, CA, USA) according to manufacturer’s instructions, and
sequences were analyzed with the 3130 Genetic Analyzer (Applied
Biosystem, Foster City, CA, USA).
All mutations are described according to the recom-
mendations of the Human Genome Variation Society
(http://www.hgvs.org/mutnomen/). The TDG reference sequence
NM 003211.4 was  from GenBank. The reference sequences used
for the other analyzed genes are listed in Table 1.
2.4. Bisulﬁte genomic sequencing analysis
Methylation analysis of the TDG promoter (cancer tissue from
Patient 1) and of four CpG dinucleotides located in the APC exon 6
and in the MLH1 exons 13 and 18 (cancer tissue from Patient 1 and
a colonic mucosa sample from a control subject) was  performed
by bisulﬁte genomic sequencing. Sodium bisulﬁte conversion of
genomic DNA was  carried out with the EpiTect Bisulﬁte kit (Qia-
gen, Hombrechtikon, Switzerland) according to the manufacturer’s
instructions. PCR products were cloned using the InsTAclone PCR
Cloning kit (Fermentas, St. Leon-Rot, Germany), and individual
clones were subjected to sequencing. Primers used for the PCR
reactions are listed in Supplementary Table 1.
2.5. Germline PMS2 and NF1 mutation analysis
Blood samples were obtained from the patient and her par-
ents after they provided written informed consent. A previously
described RNA-based mutation analysis protocol was used to
identify the germline mutations in PMS2 [17]. To conﬁrm the
presence of an identiﬁed nonsense mutation at the genomic
level, PMS2 exon 11 was  ampliﬁed from genomic DNA with
published primers [18] and subsequently sequenced. PMS2 multi-
plex ligation-dependent probe ampliﬁcation (MLPA) analysis was
used to conﬁrm a multi-exon deletion. MLPA was performed
with SALSA kits P008-A1 and P008-B1 (MRC-Holland, Amsterdam,
The Netherlands), according to the manufacturer’s instructions
using a set of six reference DNA samples each containing two
copies of PMS2- and two copies of PMS2CL-speciﬁc sequences [19].
The identiﬁed PMS2 germline mutations are described in accor-
dance with the recommendations of the Human Genome Variation
618 P. Vasovcak et al. / DNA Repa
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Society (http://www.hgvs.org/mutnomen/) using NM 000535 as
the reference sequence.
The NF1 germline mutation analysis included NF1 cDNA
sequencing as described in [20] and MLPA analysis using
SALSA kits P081-B1 and P082-B2 (MRC-Holland, Amsterdam, The
Netherlands).
3. Results
3.1. Unique mutational phenotype in a colorectal cancer
Within the framework of a large study of somatic mutations
in colorectal tumors [11], a consecutive series of 103 anonymized,
apparently sporadic colorectal cancers were examined for somatic
mutations in the APC, KRAS, TP53, BRAF, CTNNB1, and MUTYH genes,
LOH at the APC locus, MSI, and MLH1 promoter methylation. One
rectal cancer (of a patient hereafter referred to as Patient 1) stood
out from this series because of a unique mutational pattern char-
acterized by microsatellite instability (MSI+) and nine somatic
alterations, eight in APC and one in CTNNB1 (Table 1). Of note,
none of the alterations in these two genes were frameshift muta-
tions, although more than half of the mutations found in other
sporadic MSI+ colorectal cancers of this series were of this type
[11]. Furthermore, most (7/9) of the mutations in this rectal cancer
were C:G → T:A or G:C → A:T transitions, six affecting CpG dinu-
cleotides (Table 1). Since the tumor was MSI+ but MLH1 promoter
hypermethylation – a possible underlying cause of sporadic MMR
deﬁciency [5] – was not found, a germline mutation in one of the
MMR  genes was suspected to be responsible for the phenotype.
We therefore carried out mutational analysis of the MMR  genes
MLH1, MSH2 and MSH6 in colorectal tissue DNA. (At this stage of
the study, blood-derived DNA was  not available, and PMS2 was
not routinely investigated since its involvement in Lynch syndrome
was  considered rare and its sequencing was problematic [21]). This
analysis uncovered three further C:G → T:A or G:C → A:T transi-
tions (2 missense and 1 silent) at CpG dinucleotides in MLH1 and
MSH6 (Table 1). However, as these mutations were absent from the
DNA of non-neoplastic tissue, they were excluded as the underlying
germline mutations.
The peculiarity of this case prompted us to obtain the consent
of the local ethics committee for further investigation and subse-
quently to request additional information from the clinicians. This
showed that the tumor sample was derived from a teenage patient,
who  developed rectal cancer at the age of 13 years. This pheno-
type was reminiscent of constitutional mismatch repair deﬁciency
(CMMR-D) syndrome that is frequently caused by biallelic PMS2
mutations. This gene was thus thoroughly investigated (see below).
Meanwhile, tumor DNA was  also examined for mutations in NF1,
a known somatic target of CMMR-D induced mutations [22]. This
revealed four additional C:G → T:A or G:C → A:T transitions, three
of which were at CpG dinucleotides (Table 1). In summary, in this
rectal cancer, we  identiﬁed a total of 16 single-nucleotide substitu-
tions in the ∼34,000 nucleotides sequenced from 10 different genes
(exons and intron-exon boundaries). Twelve of these substitutions
(75%) affected Cs at CpG dinucleotides. Of note, four CpG sites found
mutated in APC exon 6 and MLH1 exons 13 and 18 were analyzed
exemplarily by bisulﬁte genomic sequencing and were all found to
be methylated in the colonic mucosa sample of a normal control
(Supplemental Fig. 1A)  (see Section 4).
3.2. Identiﬁcation of compound heterozygous germline PMS2
mutations in Patient 1
The complete clinical history of the 13-year-old girl affected
by the rectal cancer was obtained from our clinical collaborators.
P. Vasovcak et al. / DNA Repair 11 (2012) 616– 623 619
Fig. 1. Immunohistochemical staining of colon cancers with antibodies against MLH1, PMS2 and TDG. (A–C): Colon cancer of Patient 1; (D): colon cancer from an unrelated
CMMR-D patient with a homozygous germline PMS2 mutation (Patient 2). MLH1 expression in the tumor cells was normal (A), while its heterodimeric partner PMS2 was
absent  in the colon cancer of Patient 1 (B). PMS2 was absent also in normal stromal cells (B) and in the normal mucosa (not shown). (C) In the same cancer, expression of
the  DNA repair enzyme TDG was markedly reduced or completely absent in the nuclei. (The cytoplasmic staining may either represent background, or residual expression of
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f  this cancer with TDG pre-immune serum (negative control).
he was admitted to hospital because of recurrent episodes of
ever, pain in the lower abdomen and diarrhea. Magnetic res-
nance examination revealed a pseudotumor of the left ovary.
urgical exploration revealed a voluminous abscess, along with
everal cysts of the left ovary. Unexpectedly, tumor inﬁltration of
he recto-sigmoid junction and the left ovary from a rectal cancer
as also identiﬁed. Unilateral adnexectomy was performed, and
he histopathologic examination conﬁrmed the inﬁltration of an
ndifferentiated carcinoma. Resection of the rectal tumor was  per-
ormed one month later, and the tumor was classiﬁed as pT3N2Mx
ith moderate cell differentiation. Cycles of adjuvant therapy with
apecitabine and oxaliplatin followed by cetuximab and irinote-
an were initiated, but the treatment was interrupted after four
ycles because of lack of clinical improvement. A course of pallia-
ive radiotherapy (45 Gy/15 days) was administered thereafter and
umor growth was temporarily suppressed.
The patient had no family history of colorectal cancer and did
ot have colorectal tumors other than the rectal cancer. However,
wo café au lait maculae on the lower back were identiﬁed during
he follow-up by the clinical geneticist. This ﬁnding supported our
uspicion of CMMR-D syndrome. Since this disorder is often asso-
iated with biallelic germline mutations of the MMR  gene PMS2 [3],
ections of the rectal cancer were immunostained with anti-PMS2
ntibodies along with antibodies against the other MMR  proteins.
mmunohistochemistry showed loss of PMS2 protein in the cancer
s well as in the corresponding normal mucosa, whereas MLH1,
SH2 and MSH6 were expressed normally (Fig. 1). This staining
attern is unmistakably associated with a constitutive PMS2 gene
efect which was conﬁrmed by the identiﬁcation of compoundf the unrelated CMMR-D patient (Patient 2) used as positive control. Inset: staining
heterozygosity for two  deleterious germline PMS2 mutations in
the patient. Direct cDNA sequencing detected heterozygous loss
of exons 12, 13 and 14 (r.2007 2445del439) in PMS2 transcripts
of the patient and MLPA analysis conﬁrmed a genomic deletion
affecting these three exons (c.2007-? 2445+?del). Furthermore, the
c.1687C>T mutation leading to the premature stop codon p.Arg563*
was  identiﬁed by cDNA sequencing and conﬁrmed by sequencing
of exon 11 from genomic DNA. Analysis of parental DNA conﬁrmed
that the two  pathogenic mutations were located in trans.
Since café au lait spots and other neuroﬁbromatosis features
in CMMR-D patients may  result from postzygotic mosaic NF1
mutations detectable in blood lymphocytes [23], NF1 was  also
investigated by cDNA sequencing and MLPA, but this gene resulted
to be wild type.
Unfortunately, the radiotherapy gave only a short remission of
the disease, and the patient died 17 months later. Presently, the
patient’s parents are healthy in their forties. The only younger (now
13-year-old) sister has not been examined yet, but she has not
manifested symptoms related to CMMR-D syndrome. The maternal
father died at 53 years of age of leukemia and the paternal mother
underwent hysterectomy with adnexectomy at 40 years because of
cervical carcinoma (she is still alive at 61). No further cancer cases
were reported in the family.
3.3. Identiﬁcation of a heterozygous TDG mutation and
concomitant TDG expression loss in the neoplastic tissue
The mutational phenotype (i.e., an excess of C:G → T:A or
G:C → A:T transitions and absence of frameshift alterations) in the
620 P. Vasovcak et al. / DNA Repair 11 (2012) 616– 623
Table  2
Comparison of somatic mutations found in the tumor of Patient 1 and in tumors of three unrelated PMS2−/− patients.
Patients MSIa Somatic mutationsb
APCc (∼7000 bp) APC-MCRd (∼700 bp) CTNNB1e (∼300 bp)
Patient 1 5/5 8 (6x C>T/G>A, 1×T>G, 1×A>G) 1 (1×C>T) 1(1×C>T)
Patient  2 4/5 0 0 0
Patient  3f 5/5 n.a. 0 0
Patient 4 0/5 1 (c.4666dupA) 0 n.a.
a MSI; microsatellite instability. n.a.; not analyzed. The number of unstable markers per analyzed markers is given.
b The number of somatic mutations in the analyzed region is given (type of mutation in parenthesis).
c APC; analysis of the entire coding and ﬂanking intronic sequences of exons 1–14 and the ﬁrst 5 kb of exon 15. This region contained all somatic APC mutations found in
tumor  DNA of Patient 1.
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from the second allele must have been lost by an alternative mech-
anism, possibly a second hit that escaped detection by the methods
used in this study.APC-MCR; analysis of the mutation cluster region (MCR) only, in exon 15 of APC
e CTNNB1; analysis of the critical exon 3 and ﬂanking intronic sequences.
f Only a limited amount of tumor DNA was available from Patient 3. Therefore, o
SI+ rectal cancer of this PMS2−/− CMMR-D patient was intriguing.
o our knowledge, only one case with an inferred biallelic PMS2
ermline mutation and a high rate of somatic mutations has been
escribed to date [24]. This teenage male patient presented with
strocytoma, lymphoma, three metachronous carcinomas and mul-
iple adenomas in the colon. All analyzed tumors of this patient
ere MSI+ and frameshift mutations at short mononucleotide
epeats were also detected in exons of TGFßRII, MSH3,  MSH6 or
2F4. In addition, 11 somatic mutations in the APC and TP53 genes
ere detected in the three colorectal carcinomas (one in the ﬁrst,
our in the second and six in the third). Four of these 11 mutations
ere frameshifts and seven were single-nucleotide substitutions,
f which three were C:G → T:A or G:C → A:T transitions and only
wo were at CpG dinucleotides. This case indicates that colorectal
ancers in CMMR-D patients with biallelic PMS2 germline mutation
ay  have a high frequency of somatic mutations in their tumors,
ut do not render evidence for a preponderance of C:G → T:A or
:C → A:T mutations seen in our patient (Patient 1). Therefore, we
nalyzed colorectal cancers of three additional PMS2−/− CMMR-
 patients, who had been previously recruited and studied in our
aboratories. Mutational analysis of APC and CTNNB1 genes was
erformed in their tumor DNA (Table 2).
The ﬁrst patient (Patient 2) developed a colon adenocarcinoma
t the age of 12 years and was a homozygous carrier of a truncating
MS2 mutation (unpublished data). The genotype and phenotype
f Patient 3 were described previously [25]. Finally, we  have stud-
ed the tumor tissue of a patient (Patient 4) who developed colon
ancer at the age of 15. Although this tumor did not display insta-
ility at the microsatellites investigated to date, the patient is
ssumed to be CMMR-D due to a biallelic PMS2 germline muta-
ion since the tumor (and the normal colorectal mucosa) showed
MS2 expression loss by immunostaining in spite of normal expres-
ion of the other three MMR  proteins. Patient 4 died shortly after
he cancer diagnosis, and blood was not available to perform PMS2
ermline mutation analysis. Comparing the number of mutations
er sequenced nucleotides in the PMS2-deﬁcient colorectal can-
ers of the four CMMR-D patients, that of Patient 1 showed a far
igher frequency of somatic genetic alterations (Table 2). In fact,
nly a single alteration, an APC frameshift mutation (c.4666dupA),
as detected in the tumor of Patient 4, while no somatic sequence
hanges were found in tumors of Patients 2 and 3.
The striking preponderance of C:G → T:A or G:C → A:T transi-
ions in the somatic mutation spectrum of the rectal cancer of
atient 1 prompted us to investigate whether a defect in one of
he four uracil DNA glycosylases, UNG2, SMUG1, MBD4, and TDG
ould explain this observation. Mutational analysis of these genes
n the tumor DNA revealed a heterozygous substitution c.850G>T
n TDG, which was not present in DNA of non-neoplastic tissue
Fig. 2). This substitution resulted in a non-synonymous amino acid
hange (p.D284Y) within the catalytic core of the enzyme (residuese APC MCR  and the CTNNB1 exon 3 were sequenced.
117–300). This aspartate residue appears to have a regulatory func-
tion and is not present in non-vertebrate Mug DNA glycosylases
(Supplemental Fig. 2) [26]. Several in silico tools, i.e. Polyphen [27],
SIFT [28] and Grantham [29], predicted this variant to be “deleteri-
ous”.
Therefore, we performed immunohistochemical studies with
a polyclonal anti-TDG antibody in the tumor of Patient 1 and,
as a control, the tumor of CMMR-D Patient 2 (see Table 2). The
immunostaining showed markedly reduced nuclear TDG staining
in tumor cells of Patient 1 (Fig. 1) suggesting that the mutation
leads to instability of the protein. A mutation in the second TDG
allele was  not found, and analysis of the microdissected tumor
DNA failed to reveal LOH at the TDG locus (copy number varia-
tions at this locus were also not found using Human CGH 3 × 720 K
Whole-Genome Tiling v3.0 Array). As it was recently reported that
TDG inactivation may  promote DNA hypermethylation [30,31],  we
considered the possibility that TDG haploinsufﬁciency may  do the
same, which might have resulted in silencing of the wild type allele
in the neoplastic tissue. We  therefore carried out bisulﬁte genomic
sequencing analysis at the TDG promoter covering CpG sites shown
to be hypermethylated in multiple myeloma cell lines [32]. How-
ever, this promoter region was found to be unmethylated in this
tumor (Supplemental Fig. 1B), which implies that TDG expressionFig. 2. Sequencing electropherograms of TDG in the DNA of Patient 1. Upper panel:
sequence of the TDG gene from non-neoplastic tissue containing solely the wild
type allele. Lower panel: sequence of TDG in tumor DNA, showing the heterozygous
somatic mutation p.D284Y.
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No alteration was found in the other three uracil DNA glycosy-
ases, UNG2,  SMUG1, MBD4,  and real-time PCR analysis showed that
xpression levels of these genes in the tumor tissue are comparable
o those in the normal mucosa of the patient (primers for real-time
CR of BER genes are listed in Supplementary Table 1).
. Discussion
We describe here a CMMR-D patient (Patient 1) with a con-
titutive PMS2−/− defect, whose rectal cancer harbored, along
ith a high degree of MSI, an unexpectedly large number of
ucleotide substitutions in ﬁve of the ten tumor suppressor
enes or proto-oncogenes analyzed. The estimated rate of non-
ynonymous exonic mutations in this cancer (11 mutations in
8,547 bp exonic nucleotides analyzed = 385/Mb) was at least 67-
old higher than that of MSI-tumors (3.1–5.8/Mb according to a
hole exome next generation sequencing study [33]) and ∼8-fold
igher than that of MSI+ tumors (when considering an ∼8-times
igher rate of non-frameshift mutations in MSI+ vs. MSI-tumors
34]). Moreover, we also observed a striking preponderance of
:G → T:A and G:C → A:T transitions, 86% (12/14) of which were
ocated at CpG dinucleotides. This phenotype was observed nei-
her in colorectal cancers of three other patients with a constitutive
MS2−/− defect, nor in sporadic colorectal cancers analyzed by next
eneration sequencing [33].
A high somatic APC mutation rate was previously described in
olorectal cancers of an inferred CMMR-D patient [24], but the
umor mutation spectrum in this case showed no obvious bias for
:G → T:A and G:C → A:T transitions. Similarly, the NF1 mutation
pectrum of several MLH1−/−, MSH2−/− or MSH6−/− colon cancer
ell lines, primary colorectal cancers and mouse embryonic ﬁbrob-
asts [22] differed from that found in this gene in the rectal cancer of
atient 1. Wang and colleagues found only a single G:C → A:T tran-
ition in the MSH2−/− cancer cell line LoVo at a CpG dinucleotide
mong 10 somatic mutations, ﬁve of which were frameshifts). We
herefore conclude that the constitutional MMR  malfunction in our
MS2−/− Patient 1 was not the sole DNA repair defect responsible
or the supermutator phenotype observed in her rectal cancer.
The MMR  system processes DNA base–base mismatches and
mall insertion–deletion loops arising during DNA replication
hrough the concerted action of the four essential MMR  proteins
SH2, MSH6, MLH1 and PMS2 [35]. This system acts as a backup
f the proofreading activity of DNA polymerases and, by directing
he repair process to the nascent strand, improves the ﬁdelity of
NA replication by up to two orders of magnitude [36]. Because
nsertion–deletion loops are not addressed by the polymerase
roofreading activity, the impact of MMR  loss is easily detected
s MSI  in the DNA of MMR-deﬁcient cells. Importantly, in Lynch
yndrome patients, MSI  is present only in tumor cell DNA, due
o somatic inactivation of the wild type allele [37]. In contrast,
MMR-D patients are born with a biallelic, germline inactivation of
ne of the MMR  genes, and therefore have a MMR  defect in all cells
38,39]. Indeed, in a previous study [40], frameshifts in microsatel-
ites were found more frequently in the DNA of non-neoplastic
issues of a PMS2−/− deﬁcient individual than in the corresponding
ormal tissues of a heterozygous PMS2+/− individual and a PMS2+/+
ontrol subject.
In contrast to MMR, BER functions predominantly in non-
eplicating DNA [41]. The repair process is initiated by one of several
NA glycosylases, which are highly substrate-speciﬁc. In the case
f cytosine deamination, the product of the reaction, uracil, can
e removed from DNA by one of four enzymes: UNG2, SMUG1,
BD4 or TDG. UNG2 is the major effector of uracil repair, whereas
MUG1 is believed to act as a broad-speciﬁcity back-up, especially
n non-replicating chromatin [42,43].ir 11 (2012) 616– 623 621
5-Methylcytosine deaminates to thymine and it has been pos-
tulated that methylated CpGs are mutagenic hotspots because
thymines arising through deamination cannot be distinguished
from other thymines in DNA. However, 5-methylcytosine deam-
ination generates a T/G mispairs in DNA and it could be shown
that these are efﬁciently reverted to C/G by BER [44,45], which
is initiated by TDG [46]. A decade later, MBD4, a second enzyme
capable of removing T from T/G mispairs was  identiﬁed [47,48].
The identiﬁcation of an apparently pathogenic somatic mutation in
TDG that is linked with substantially lower levels of the protein in
the tumor of Patient 1, and the striking predominance of C:G → T:A
and G:C → A:T transitions at CpG dinucleotides in the tumor DNA
strongly supports the hypothesis that TDG is the key enzyme pro-
tecting our genome from mutagenesis at methylated CpGs. When
we  studied the methylation status of some of the CpGs found to
be mutated in the tumor of Patient 1 in a colonic mucosa sam-
ple of a normal individual, cytosines in all the investigated CpG
sites were found to be methylated. Thus, it is highly likely that
the observed point mutations were caused by deamination of 5-
methylcytosine to thymine, which remained uncorrected owing to
the TDG deﬁciency in this tumor.
Aberrant activation of the Wnt  signaling pathway is one of the
key early events in the transformation of colonic epithelium, and
APC mutations are among the most common aberrations detected
in colorectal cancers (reviewed in [49]). The tumor DNA of Patient
1 was  no exception in this regard: it contained eight somatic
APC alterations, two  of which (c.646C>T, p.R216* and c.694C>T,
p.R232*) were clearly pathogenic and on different alleles (as deter-
mined by mutant allele-speciﬁc PCR ampliﬁcation and subsequent
sequencing of the generated PCR product (data not shown) and as
conﬁrmed by bisulﬁte genomic sequencing analysis of APC exon 6
(see Supplemental Fig. 1A). Like most mutations identiﬁed in the
rectal tumor of Patient 1, they were C:G → T:A transitions, and thus
might have arisen as a result of TDG deﬁciency, assuming that,
within the context of this tumor, TDG inactivation preceded that
of APC. This does not seem unreasonable, given that the TDG  muta-
tion was a G → T transversion, a characteristic footprint of oxidative
DNA damage and/or MMR  deﬁciency, rather than a C → T transition
typical of deamination.
This is to our knowledge the ﬁrst study describing a somatic
mutation of TDG in a human tumor. This mutational event was
presumably selected for during early tumorigenesis in cells with
a high mutation rate caused by a constitutive MMR  defect, but,
since TDG was  not inactivated in tumors of three other CMMR-D
patients, the loss of this enzyme is likely not an obligate step in
the malignant transformation of the colonic epithelium of such
patients. However, TDG inactivation might have contributed to the
aggressive phenotype of the rectal tumor in Patient 1, given that a
loss of this activity renders the tumor DNA more prone to acquire
mutations at CpG sites. In any case, this tumor offered the unique
opportunity to study TDG loss in vivo. Our ﬁnding that TDG loss
leads to C → T transitions at methylated CpGs in vivo demonstrates
that this enzyme indeed protects our genomes against deleterious
effects of 5-methylcytosine deamination, as predicted more than
20 years ago [45].
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